Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry
- PMID: 24483945
- DOI: 10.3109/08037051.2013.876771
Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry
Abstract
Background: Recent guidelines recommended different approaches to hypertension therapy. Our aim was to evaluate trends in blood pressure (BP) management among patients admitted with acute stroke over the past decade.
Methods: The study population comprised 6279 consecutive patients, admitted with an acute stroke, and included in a national registry of three consecutive periods conducted during the years 2004-2010. We compared patients' characteristics and temporal trends of antihypertensive therapy utilization before hospital admission.
Results: Among 4727 hypertensive patients, 3940 (83%) patients have taken antihypertensive drug therapy - 1430 (30.2%) a single agent, 1500 (31.7%) two agents and 1010 (21.4%) three or more antihypertensive agents. The most common class used was renin-angiotensin system (RAS) blockers (n = 2575; 54%) followed by beta-blockers (n = 2033; 43%). The same pattern was observed in patients treated with monotherapy. The use of RAS blockers and beta-blockers has increased over the years (p < 0.001 for both), whereas the use of diuretics decreased and the use of calcium antagonists remained stable. Among those who were treated with a single agent, the use of diuretics and calcium antagonists decreased and the use of RAS blockers increased, whereas the use of beta-blockers remained unchanged.
Conclusions: RAS blockers and beta-blockers are the most common antihypertensive agents used in Israel. Over time, the use of RAS blockers and beta-blockers has increased, whereas the use of diuretics decreased.
Keywords: Beta-blockers; calcium antagonists; diuretics; drugs; hypertension therapy; renin–angiotensin-system blockers.
Similar articles
-
Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.J Am Pharm Assoc (2003). 2010 Sep-Oct;50(5):e116-25. doi: 10.1331/JAPhA.2010.09234. J Am Pharm Assoc (2003). 2010. PMID: 20833609 Review.
-
Antihypertensive treatment and risk of atrial fibrillation: a nationwide study.Eur Heart J. 2014 May;35(18):1205-14. doi: 10.1093/eurheartj/eht507. Epub 2013 Dec 17. Eur Heart J. 2014. PMID: 24347316
-
Use of Antihypertensive Drugs and Ischemic Stroke Severity - Is There a Role for Angiotensin-II?PLoS One. 2016 Nov 15;11(11):e0166524. doi: 10.1371/journal.pone.0166524. eCollection 2016. PLoS One. 2016. PMID: 27846309 Free PMC article.
-
Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.Am J Hypertens. 2012 Mar;25(3):379-88. doi: 10.1038/ajh.2011.216. Epub 2011 Dec 8. Am J Hypertens. 2012. PMID: 22158065
-
Development and trends in the drug treatment of essential hypertension.J Hypertens Suppl. 1992 Dec;10(7):S1-12. J Hypertens Suppl. 1992. PMID: 1363322 Review.
Cited by
-
Incidence, aetiology and mortality secondary to hypertensive emergencies in a large-scale referral centre in Israel (1991-2010).J Hum Hypertens. 2016 Aug;30(8):498-502. doi: 10.1038/jhh.2015.115. Epub 2015 Dec 17. J Hum Hypertens. 2016. PMID: 26674757
-
Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network.J Am Heart Assoc. 2023 Jan 3;12(1):e026652. doi: 10.1161/JAHA.122.026652. Epub 2022 Dec 24. J Am Heart Assoc. 2023. PMID: 36565195 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous